Key features and details
- Expression system: Baculovirus infected Sf9 cells
- Purity: >= 57% SDS-PAGE
- Active: Yes
- Tags: GST tag N-Terminus
- Suitable for: Functional Studies, SDS-PAGE
Product nameRecombinant human PDE4D7 protein (Active)
Biological activitySpecific Activity: ≥ 10,000 pmol/min/µg.Unit Definition: One unit is defined as the amount of enzyme that will convert 1 pmole of 3', 5'-cAMP to 5'-AMP per minute at 37°C.Assay Conditions: 10 mM Tris-HCl, pH 7.4, 10 mM MgCl2, 0.1 mg/ml BSA, 0.05% Tween-20, 200 µM cAMP, 2.5 kU 5'-nucleotidase, and serial dilutions of PDE4D7 at 37°C for 20 min. Quantified by 5'- nucleotidase cleaving the 5' -AMP product and releasing the phosphate group which is detected by Malachite Green Reagent.
Purity>= 57 % SDS-PAGE.
Expression systemBaculovirus infected Sf9 cells
Protein lengthFull length protein
Predicted molecular weight111 kDa including tags
Amino acids2 to 748
TagsGST tag N-Terminus
Our Abpromise guarantee covers the use of ab271681 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Concentration information loading...
Preparation and Storage
Stability and Storage
Shipped on Dry Ice. Store at -80°C. Avoid freeze / thaw cycle.
Constituents: 0.71% Tris HCl, 0.64% Sodium chloride, 0.02% Potassium chloride, 0.05% (R*,R*)-1,4-Dimercaptobutan-2,3-diol, 0.61% Glutathione, 10% Glycerol (glycerin, glycerine)
This product is an active protein and may elicit a biological response in vivo, handle with caution.
RelevanceCyclic AMP dependent phosphodiesterase type D (PDE4D) family is comprised of 5 variants (PDE4D1, D2, D3, D4, D6, D7, and D8; 1, 2). One or more PDE4D subtype variants are ubiquitously present in all mammalian cells. In CNS all five PDE4D subtype variants are expressed in varying ratios, and their activity is regulated in tandem with GPCRs stimulation and selective phosphorylation by PKA and other kinases. Peripheral tissues also exhibit differential expression of PDE4D variants. PDE4D1/D2 mRNA levels rise in response to an increase in cAMP. Short term regulation of PDE4D variants involved PKA, MAP kinases and Erk2 phosphorylation that results in rapid change in their enzymatic activities. Other regulatory mechanism involved protein protein interactions with cytoskeletal scaffolding proteins. Anti PDE4D antibodies are ideal tools for studying regulation, expression, phosphorylation, and protein protein interactions of PDE4D variants employing pull down immunoprecipitation protocol.
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
ab271681 has not yet been referenced specifically in any publications.